IGF1R and cancer: Early clinical trials of IGF-1R inhibitors showed potentially promising results in these rare cancers (121, 122), but unfortunately, the IGF-1R and insulin receptor inhibitor linsitinib showed limited therapeutic benefit in a recent phase III trial (123).